Stingray Therapeutics INC
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersHouston, TX
SAM.gov UEIXNADTMZYJMP5
Stingray Therapeutics develops Vizenpistat (SR-8541A), an ENPP1 inhibitor for cancer immunotherapy that is currently in clinical trials across multiple cancer indications. The company's approach targets innate immunity by blocking ENPP1 to reactivate the cGAS-STING pathway.
Summarized from the company’s own website
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Stingray Therapeutics INC | Houston | TX | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.